AURIGENE ONCOLOGY LIMITED
Location
Karnataka
Founded
2001-08-10
Website
Risk Signals
7 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about AURIGENE ONCOLOGY LIMITED
Live alerts from global media, monitored by Business Radar
2025-04-03 (webwire.com)
Edity Therapeutics Enters into a Strategic Co-Development Partnership with Aurigene Oncology to Advance a Novel Cell Therapy Program for Solid Tumors |
Edity Therapeutics Limited and Aurigene Oncology Limited (AOL), a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited, a clinical-stage biotechnology company, announced a strategic collaboration to create novel cell therapy medicines for difficult-to-treat solid tumors. , , , , The partnership is bolstered by government grants awarded to both companies. Aurigene Oncology secured grant from the India-Israel Industrial R&D and Technology Innovation Fund, while Edity received non-diluti...
Read more